CA
LFCR icon

Cliff Asness’s Lifecore Biomedical LFCR Stock Holding History

Cliff Asness’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$292K Buy
55,613
+39,743
+250% +$200K ﹤0.01% 3634
2026
Q1 		$59K Sell
15,870
-301
-2% -$2.08K ﹤0.01% 3708
2025
Q4 		$132K Buy
16,171
+3,574
+28% +$26.4K ﹤0.01% 3437
2025
Q3 		$92.7K Buy
12,597
+1,146
+10% +$8.67K ﹤0.01% 3376
2025
Q2 		$93K Buy
+11,451
New +$77.2K ﹤0.01% 3189
2022
Q3 		– Sell
-21,782
Closed -$217K – 2263
2022
Q2 		$217K Sell
21,782
-29,093
-57% -$288K ﹤0.01% 1974
2022
Q1 		$589K Sell
50,875
-10,108
-17% -$113K ﹤0.01% 1756
2021
Q4 		$677K Buy
60,983
+1,379
+2% +$13.4K ﹤0.01% 1720
2021
Q3 		$550K Buy
59,604
+3,073
+5% +$33.4K ﹤0.01% 1829
2021
Q2 		$636K Sell
56,531
-4,950
-8% -$57.1K ﹤0.01% 1802
2021
Q1 		$652K Buy
+61,481
New +$691K ﹤0.01% 1735
2020
Q4 		– Sell
-20,658
Closed -$201K – 2229
2020
Q3 		$201K Buy
+20,658
New +$197K ﹤0.01% 2059

Other funds holding LFCR

WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

Cliff Asness's LFCR Position: Q2 2026 in Review

Cliff Asness increased its Lifecore Biomedical (LFCR) stake by 250% in Q2 2026, buying an estimated $200K and bringing the position to 55,613 shares worth $292K. The position accounts for ﹤0.01% of the portfolio, ranked #3634.

Cliff Asness first reported a position in LFCR in Q3 2020 and has held it in 12 quarters since. The position peaked at $677K in Q4 2021. 98 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • Cliff Asness held 55,613 shares of Lifecore Biomedical worth $292K as of Q2 2026.
  • Cliff Asness bought 39,743 Lifecore Biomedical shares in Q2 2026, an estimated $200K.
  • Lifecore Biomedical made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #3634 holding.
  • Cliff Asness first reported a position in Lifecore Biomedical in Q3 2020 and has held it in 12 quarters since.
  • Cliff Asness's Lifecore Biomedical position peaked at $677K in Q4 2021.
  • 98 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.